In the current study, we found that knockdown of FGL1 led to clearly enhanced the expression of cleaved caspase 3 and cleaved PARP1, and overcame acquired resistance to gefitinib in NSCLC cells both in vitro and in vivo. The gene discussed is PARP1; the disease is non-small cell lung carcinoma.